European Commission approves Roche ’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
Roche today announced that the European Commission (EC) has granted a marketing authorisation for Alecensa ® (alectinib) as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Lymphoma | Marketing | Non-Small Cell Lung Cancer | Pharmaceuticals